7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
| Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
| Kim KJ et al. | Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. | 2001 | J. Biomed. Mater. Res. | pmid:11410897 |
| Abu-Amer Y | IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. | 2001 | J. Clin. Invest. | pmid:11390419 |
| Kon T et al. | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | 2001 | J. Bone Miner. Res. | pmid:11393777 |
| Fazzalari NL et al. | The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. | 2001 | J. Bone Miner. Res. | pmid:11393778 |
| Bekker PJ et al. | The effect of a single dose of osteoprotegerin in postmenopausal women. | 2001 | J. Bone Miner. Res. | pmid:11204435 |
| Kikuchi T et al. | Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. | 2001 | J. Immunol. | pmid:11207318 |
| O'Brien EA et al. | Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. | 2001 | Bone | pmid:11182380 |
| Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Takemura M et al. | Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. | 2001 | Metab. Clin. Exp. | pmid:11172466 |
| Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
| Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |
| Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
| Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
| Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
| Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
| Lean JM et al. | FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. | 2001 | Blood | pmid:11675341 |
| Fiumara P et al. | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | 2001 | Blood | pmid:11675352 |
| Satoh K et al. | Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. | 2001 | Pancreas | pmid:11590320 |
| Yano K et al. | Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11594776 |
| Brown JM et al. | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. | 2001 | Clin. Cancer Res. | pmid:11595685 |
| Price PA et al. | Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11597934 |
| Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
| Kuntz KA et al. | An immunohistochemical study of osteoprotegerin in the human dental pulp. | 2001 | J Endod | pmid:11716077 |
| Hofbauer LC and Schoppet M | Serum measurement of osteoprotegerin--clinical relevance and potential applications. | 2001 | Eur. J. Endocrinol. | pmid:11720890 |
| Ueland T et al. | Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. | 2001 | Eur. J. Endocrinol. | pmid:11720891 |
| Chikazu D et al. | Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. | 2001 | J. Bone Miner. Res. | pmid:11697804 |
| Khosla S | Minireview: the OPG/RANKL/RANK system. | 2001 | Endocrinology | pmid:11713196 |
| Seidel C et al. | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. | 2001 | Blood | pmid:11568016 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
| Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
| Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
| Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
| Seck T et al. | Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. | 2001 | Eur. J. Endocrinol. | pmid:11454517 |
| Burguera B et al. | Leptin reduces ovariectomy-induced bone loss in rats. | 2001 | Endocrinology | pmid:11459801 |
| Yamagishi T et al. | Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. | 2001 | Endocrinology | pmid:11459812 |
| Ma YL et al. | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. | 2001 | Endocrinology | pmid:11517184 |
| Bateman TA et al. | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. | 2001 | J. Orthop. Res. | pmid:11518255 |
| Myoung H et al. | Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. | 2001 | J. Periodont. Res. | pmid:11519698 |
| Haynes DR et al. | The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. | 2001 | J Bone Joint Surg Br | pmid:11521937 |
| Hofbauer LC and Schoppet M | Osteoprotegerin: a link between osteoporosis and arterial calcification? | 2001 | Lancet | pmid:11498208 |
| Sakai A et al. | 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. | 2001 | J. Bone Miner. Metab. | pmid:11498729 |
| Ikeda T et al. | Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. | 2001 | J. Bone Miner. Res. | pmid:11499864 |
| Thomas GP et al. | Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. | 2001 | J. Endocrinol. | pmid:11479141 |
| Allan GF et al. | Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. | 2001 | Steroids | pmid:11546554 |
| Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
| Halladay DL et al. | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. | 2001 | J. Cell. Biochem. | pmid:11746511 |
| Cao Y et al. | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. | 2001 | Cell | pmid:11747812 |
| Chung H et al. | Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. | 2001 | J. Korean Med. Sci. | pmid:11748360 |
| Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
| Lindberg MK et al. | Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. | 2001 | J. Endocrinol. | pmid:11739008 |
| Giuliani N et al. | Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. | 2001 | Blood | pmid:11739153 |
| Croucher PI et al. | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. | 2001 | Blood | pmid:11739154 |
| Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
| Ramalho AC et al. | Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. | 2001 | Cytokine | pmid:11792122 |
| Yano K et al. | Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. | 2001 | J. Bone Miner. Metab. | pmid:11685652 |
| Kawahara N et al. | Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. | 2001 | Chem. Pharm. Bull. | pmid:11605678 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |
| Yan T et al. | Regulation of osteoclastogenesis and RANK expression by TGF-beta1. | 2001 Aug 1-9 | J. Cell. Biochem. | pmid:11573248 |
| Rosa-Rañal M et al. | [New paradigms in the regulation of bone metabolism]. | 2001 Jul-Aug | Rev. Invest. Clin. | pmid:11599485 |
| Lee SK and Lorenzo JA | Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. | 2002 | Bone | pmid:12110442 |
| Shioi A et al. | Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. | 2002 | Circ. Res. | pmid:12114316 |
| Lipton A et al. | Serum osteoprotegerin levels in healthy controls and cancer patients. | 2002 | Clin. Cancer Res. | pmid:12114435 |
| Fujita T et al. | SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. | 2002 | J. Oral Pathol. Med. | pmid:12201246 |
| Juji T et al. | A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders. | 2002 | J. Bone Miner. Metab. | pmid:12203031 |
| Grisar J et al. | Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. | 2002 | J. Rheumatol. | pmid:12136902 |
| Iida-Klein A et al. | Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. | 2002 | J. Bone Miner. Res. | pmid:12009011 |
| Jain RG and Lenhard JM | Select HIV protease inhibitors alter bone and fat metabolism ex vivo. | 2002 | J. Biol. Chem. | pmid:11937496 |
| Ariyasu T et al. | Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. | 2002 | In Vitro Cell. Dev. Biol. Anim. | pmid:11963965 |
| Bateman TA and Countryman S | Osteoprotegerin and bone loss associated with spaceflight. | 2002 | Drug Discov. Today | pmid:11965392 |
| Price PA et al. | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. | 2002 | J. Bone Miner. Res. | pmid:12096831 |
| Xing L et al. | NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. | 2002 | J. Bone Miner. Res. | pmid:12096833 |
| Zou W and Bar-Shavit Z | Dual modulation of osteoclast differentiation by lipopolysaccharide. | 2002 | J. Bone Miner. Res. | pmid:12096834 |
| Yang SY et al. | Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. | 2002 | Arthritis Rheum. | pmid:12355500 |
| Suda T et al. | [Merger of bone biology and immunology]. | 2002 | Tanpakushitsu Kakusan Koso | pmid:12385106 |
| Nagasawa T et al. | LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. | 2002 | Clin. Exp. Immunol. | pmid:12390325 |
| Takahashi E et al. | High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. | 2002 | J. Med. Dent. Sci. | pmid:12641381 |
| Ito S et al. | Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. | 2002 | J. Biol. Chem. | pmid:11733492 |
| Holen I et al. | Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. | 2002 | Cancer Res. | pmid:11912131 |
| Mori H et al. | RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. | 2002 | Histochem. Cell Biol. | pmid:11914926 |
| Scatena M and Giachelli C | The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. | 2002 | Trends Cardiovasc. Med. | pmid:11852256 |
| Hofbauer LC and Kühne CA | Cytokine inhibition: a new therapeutic avenue for skeletal diseases. | 2002 | Drug Discov. Today | pmid:11854049 |
| Viereck V et al. | Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. | 2002 | Biochem. Biophys. Res. Commun. | pmid:11855844 |
| Romas E et al. | Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. | 2002 | Bone | pmid:11856640 |
| Viereck V et al. | Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. | 2002 | J. Cell. Biochem. | pmid:11835398 |
| Cho CH and Nuttall ME | Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. | 2002 | Expert Opin. Ther. Targets | pmid:12472380 |
| Hasegawa T et al. | Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. | 2002 | J. Periodont. Res. | pmid:12472833 |
| Yamashita T et al. | Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. | 2002 | Endocrinology | pmid:12446599 |
| Whyte MP and Hughes AE | Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. | 2002 | J. Bone Miner. Res. | pmid:11771666 |